Compounds > phosphorylcholine

phosphorylcholine and mk 2206

phosphorylcholine has been researched along with mk 2206 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, JQ; Coppola, D; Guo, JP1
Liu, D; Liu, R; Xing, M1
Dedes, KJ; Fink, D; Gutsche, K; Imesch, P; Samartzis, EP; Stucki, M1
Cani, A; Capitani, S; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Tabellini, G; Ultimo, S; Zauli, G1
Chen, F; Ji, F; Liu, W; Mao, L; Wang, S; Xie, Y1
Haniuda, M; Hosokawa, Y; Hyodo, T; Karnan, S; Konishi, H; Ota, A; Tsuzuki, S; Wahiduzzaman, M; Yamaji, M1
Bjune, K; Naderi, S; Wierød, L1

Other Studies

7 other study(ies) available for phosphorylcholine and mk 2206

ArticleYear
IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
    The Journal of biological chemistry, 2011, Oct-28, Volume: 286, Issue:43

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Activation; Female; Gene Deletion; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Mammary Neoplasms, Animal; Mice; Mice, Knockout; NIH 3T3 Cells; Oxadiazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Ribonucleosides; Trans-Activators; Transcription Factors

2011
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Proliferation; Down-Regulation; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Glutamic Acid; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Mutant Proteins; Oncogene Protein v-akt; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Thyroid Neoplasms; Tumor Cells, Cultured; Valine; Vemurafenib

2012
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
    Oncotarget, 2014, Jul-30, Volume: 5, Issue:14

    Topics: Aminopyridines; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection

2014
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Oncotarget, 2015, Mar-30, Volume: 6, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Cycle Checkpoints; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Heterocyclic Compounds, 3-Ring; Humans; Jurkat Cells; Molecular Targeted Therapy; Oxadiazoles; Phosphatidylinositol 3-Kinase; Phosphorylation; Phosphorylcholine; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases

2015
Icariside II activates EGFR-Akt-Nrf2 signaling and protects osteoblasts from dexamethasone.
    Oncotarget, 2017, Jan-10, Volume: 8, Issue:2

    Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Chromones; Dexamethasone; ErbB Receptors; Flavonoids; Heterocyclic Compounds, 3-Ring; Mice; Morpholines; NF-E2-Related Factor 2; Osteoblasts; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction

2017
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
    Cancer medicine, 2017, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Box Protein O1; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inhibitory Concentration 50; Mesothelioma; Oxadiazoles; Phosphorylation; Phosphorylcholine; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinoxalines; Sulfonamides; Thiadiazoles; Thiophenes

2017
Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Aminopyridines; Animals; Benzimidazoles; CHO Cells; Cricetinae; Cricetulus; Hep G2 Cells; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Phosphorylcholine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, LDL; Ribonucleosides; RNA Stability; RNA, Messenger; Transcriptional Activation

2019